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ABSTRACT
Background: Opioid consumption is at an alarming rate in the United States. Their side effects
have attracted debates on whether they are indispensable and continuously prompt further
consideration of alternative approaches. Recent studies have suggested that dexmedetomidine has
a good analgesic profile and can reduce opioid consumption. Additional studies are warranted to
establish whether dexmedetomidine as an adjunct therapy can influence opioid consumption in
surgical units.
Objectives: This literature review aimed to evaluate the current randomized controlled trials
(RCTs) on the impact of dexmedetomidine as adjunct therapy on opioid consumption and further
recommend best available practices on the current issue.

Methodology: Seven randomized control trials (RCTs) were evaluated in this systematic
review. The RCTs found a statistically significant decrease in opioid consumption with
the application of dexmedetomidine in patients receiving spinal anesthesia. With this
information, a pre-test, educational module, and post-test were created for anesthesia
providers to evaluate both baseline knowledge and knowledge growth.
Results: The evidence search and screening resulted in 7 RCTs. Three studies demonstrated
dexmedetomidine infused at the induction of anesthesia to reduce post-operative and
perioperative opioid consumption. Four studies demonstrated dexmedetomidine to reduce
cumulative opioid consumption when administered before induction of anesthesia. One study
demonstrated intranasal dexmedetomidine to impact cumulative opioid consumption.
Conclusion: Evidence shows that dexmedetomidine as adjunct therapy reduces opioid
consumption preoperatively and post-operatively. The least effective dose is 0.5 μg/kg-1 μg/kg,
and can be infused before or at the induction of anesthesia.
Keywords: Dexmedetomidine, opioids, spinal anesthesia, opioids consumption, surgical units,
surgery, postoperative, perioperative.
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INTRODUCTION
Description of the Problem
The current situation in the US is that opioid consumption during surgical operations is
significantly high. Nearly all US patients are prescribed and receive opioids during surgery. 1
Opioids are generally approved by the FDA to be used in every phase of surgery. Uses may
include during induction and maintenance of anesthesia, control of postoperative pain, and to
reduce agitation. The most commonly used are IV preparations of morphine, fentanyl, and
hydromorphone. These uses have made healthcare centers a major dispensation point for opioids
and have made opioids nearly essential in American surgical rooms. In a retrospective study, the
mean daily consumption for opioids among women who underwent caesarian surgery was 48.6%,
and morphine was 44.6% 2. The issue does not stop in surgical wards; 6% of previously opioid
naïve surgical patients continue taking opioids 3-6-month post-surgery. 1 For an extended time,
surgical wards have been a vehicle for high opioid use in the American community. Clinicians
attending to patients throughout the perioperative period find this situation a major concern.
Background
The use of opioids has presented devastating challenges to US public health and
individual health. On October 26, 2016, the United States president declared the opioid epidemic
a public health emergency in the US.3 Over the past two decades, the incidence of overdoserelated deaths has markedly increased.4 The death rate rose to 46,802 (65% of total drug
overdose-related deaths) in 2018.5 These statistics do not represent other long term impacts such
as sexual abuse, opioid use disorder, nutritional neglect, and children born to opioid-dependent
mothers.6 The deadly nature of the opioid epidemic is clear and warrants an upstream approach.
The opioid epidemic is hindered by diverse players. Pharmaceutical manufacturers have
contributed to the crisis by marketing pain drugs and impressing them on patients. 7 Political and
social influences have also contributed. Of the many participants, the healthcare sector cannot be
ignored. The opioid crisis ideally combines both prescription and non-prescription opioid use.
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According to the Centers for Disease Prevention and Control (CDC), two out of three drug
overdoses are caused by prescription opioids, heroin, or synthetic opioids.7 99% of USA surgical
patients receive opioid prescriptions perioperatively.1 Many of the patients that develop substance
abuse tend to have a history of surgical procedures, supporting the notion that opioid use begets
opioid use.8 Generally, the healthcare system, particularly surgical units, significantly contribute
to the opioid crisis and warrant further investigation.
Opioids are consistently prescribed in surgical units with the intent of providing effective
pain management. Opioids provide reliable analgesia for prolonged periods of time, however,
clinicians are extensively trained to be judicious in their administration.9 Opioids like fentanyl,
hydromorphone, morphine, oxycodone, oxymorphone, and tramadol have been persistently used
in various perioperative phases, including pre-induction, induction of anesthesia, maintenance,
reduction of immediate postoperative pain, and to decrease agitation.10 During surgery, they are
often administered intravenously as an adjunct medication to blunt sympathetic responses.
Opioids administered for postoperative pain or breakthrough pain (experiencing pain while
currently on an acute or chronic pain regimen) is also known as rescue analgesia. If opioids were
consistently prescribed in surgical units with overt caution, there is often little need for alarm. 11
However, their use has presented the US healthcare system with challenges in public and
individual health.
Opioid use in surgical units has been associated with many adverse effects. The primary
effect, as discussed in earlier paragraphs, is opioid dependence and the larger opioid crisis.
Patients who have been prescribed opioids as the leading pain management modality have often
required higher doses of opioids to maintain analgesia.1 Adverse effects like opioid-induced
endocrinopathy, hyperalgesia, respiratory depression, urinary retention, postoperative respiratory
depression, bradycardia, and somnolence have also been reported. 10,12 These adverse effects
warrant alternative adjunct therapies during surgery.
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Dexmedetomidine has been documented as a potential adjunct for opioid administration.
Dexmedetomidine is a highly selective α2-adrenergic receptor (α2-AR) agonist that has sedative
and analgesic effects. According to Seongheon, dexmedetomidine may provide stable
hemodynamics, minimal respiratory depression, and produce less delirium. 13 The concept of
minimal respiratory depression is significant in that it is often observed in many analgesics. Even
at higher doses, dexmedetomidine does not cause significant respiratory depression. Patients
under dexmedetomidine have a comfortable sleep to wakefulness transition. This drug produces
profound sedation at higher doses and has both spinal and peripheral action. These attributes
suggest dexmedetomidine as a superior analgesic supplement to reduce opioid use compared to
other analgesics.
Scope of the Problem
Indeed, many Americans are affected by the opioid crisis or epidemic. In 2018, it was
reported that 10.3 million Americans 12 years and older partook in the misuse of opioids 14. Out
of the 10.3 million, 9.9 million Americans misused pain prescription opioids 14. These numbers
cut across all demographic factors, including age, race/ethnicity, gender, geographical groups,
and across all socioeconomic cadres. The trend for opioid use has sharply been increasing.
Between 2016-2018, there was a 146% increase in patients with opioid-related treatments 14.
These statistics exemplify how the US is susceptible to the opioid crisis and that the surgeon
general was in order to call it an epidemic.
The rate of opioid consumption alone should not be considered the sole reason for
addressing the opioid crisis. Statistics regarding opioid-related mortalities are significant and
concerning. Since 1999, more than 760,000 Americans have died from an opioid overdose 14.
Opioid-related overdose deaths have tripled in the past eighteen years. These mortalities are
significantly high and necessitate addressing 14. If the opioids crisis is not attacked from multiple
target points, the mortalities may increase to more than fourfold in the future.
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Consequences of the Problem
Opioid use causes devastating effects on individuals and patients. In the perioperative
period, opioid use may cause urinary retention, increased length of hospital stay, respiratory
depression, and constipation. 12 Post-surgery, effects like immunosuppression, endocrinopathy,
and hyperalgesia have been noted. Patients which chronic respiratory conditions are often at high
risk. The most glaring impact is opioid addiction and use disorder, which increases the risk of
endocarditis, infections, and narcotic bowel syndrome. Despite these issues being understood by
healthcare providers, they are often understated 12. In the end, patients have higher chances of
morbidity and mortality.
The above consequences can be quantified in terms of cost. The US spends more than
$78.5 billion annually to manage opioid-related complications, abuse, and loss of productivity. 12
Between 2016-2019, $9 billion was granted to fight the opioid crisis. 14 Post-surgery, patients with
opioid abuse disorders spend at least 21% higher healthcare readmission costs than their opioidfree counterparts.16 These high costs augmented by earlier mentioned consequences should
compel stakeholders and policymakers to find feasible solutions. No solution may be considered
absolute for the opioid epidemic. However, an excellent starting point would be through
anesthesiologists, nurse anesthetists, and perioperative pain management.
Knowledge Gaps
As earlier stated, the use of opioids in surgical units is almost indispensable. As Egan
(2019) illustrates, using one drug to produce anesthesia has been a long-term challenge. 17
Available medications like propofol require higher concentrations to cause unconsciousness and
immobility. To this end, opioids have been considered a better adjunct to control the autonomic
nervous system. Their effect on nociception-induced arousal is widely known. Also, opioids have
been fundamentally used to control postoperative pain, which may increase morbidity and
mortality if poorly controlled.
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Studies are currently underway to demonstrate opioid-sparing modalities that can produce
comparable analgesic effects. Such options should confer greater benefit than risks to a surgical
candidate. These studies demonstrate varied results depending on their settings and doses of their
candidate drugs. Notably, many drugs have been proposed, but there is no consensus on a specific
compound. This contention creates a knowledge gap that compels one to think and explore how
to replace opioids.
Proposed Solution
Amid the current contention, this research proposes dexmedetomidine as a pain
management adjunct and possible solution to help battle the opioid crisis. Dexmedetomidine is a
highly selective α2-adrenergic receptor (α2-AR) agonist that produces analgesic effects and
sedation. 18 The FDA approved this medication in 1999 for use in critically ill patients. The
medication was approved for procedural sedation in 2008 for non-intubated patients. This latter
approval broadened the use of dexmedetomidine for patients requiring spinal anesthesia.
Dexmedetomidine is a possible solution because studies continue to show promising
benefits. Dexmedetomidine has better hemodynamic stability and produces superior pain control
than selected opioids. 18 Using dexmedetomidine during nerve block has demonstrated a
reduction in perioperative pain along with reduced risk of respiratory depression. 19 The above
findings suggest that dexmedetomidine would be an ideal solution to help counteract the adverse
effects of opioid use and ultimately the opioid crisis.
Literature Review Rationale
Opioids are consistently used throughout the perioperative period. More than 80% of the
51 million Americans who undergo surgery annually are prescribed opioids for acute pain
management12. The most commonly prescribed opioids include oxycodone and hydrocodone.
According to Wilson, these two opioids medications are the leading causes of opioid overdose
and death in the US 6. Surgical units appear to be a significant dispatch point for this unfortunate
trend. Aside from the opioid crisis, opioid use has been associated with many postoperative
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adverse effects. These long-standing issues draw attention to modalities that could reduce opioid
consumption in surgical units. Such modalities can consequentially reduce opioid's impact on the
general American population. Theories posit dexmedetomidine as a favorable alternative and can
be supported through evidence. The purpose of this literature review is to discern whether there is
evidence that dexmedetomidine as an analgesic could reduce perioperative consumption of
opioids.

METHODOLOGY
Information Sources and Search Strategy
The literature sample was obtained from various databases. The PICOT question that
guided the search was, “In the surgical patient undergoing spinal anesthesia (S), how does the use
of dexmedetomidine as an anesthetic adjunct (I), compared to its non-use (C), affect the
postoperative (or perioperative) consumption of opioids (O)?” Once this question was formulated,
various phrases were coined for use in the databases. The key phrases “dexmedetomidine and
opioids," "dexmedetomidine and spinal anesthesia," "dexmedetomidine and opioids
consumption," and "reducing opioids consumption" were used. Databases such as MedLine,
Cumulative Index of Nursing and Allied Health Literature (CINAHL), Excerpta Medica Database
(EMBASE), Pubmed and Google Scholar were used. authorities have agreed that these are the
most useful bibliographic databases for nurses.20
While searching through the databases, various qualifiers were used to narrow the results.
The database’s filters were set to produce articles published from 2016 to 2020 because
restricting the year of publication allows the limitation of outdated studies while highlighting
current data. The search was further filtered to allow only systematic reviews, randomized
controlled trials, or meta-analysis being that such resection makes results more specific and
allows one to obtain quality evidence. The search also allowed full text as opposed to abstracts,
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though some of these restrictions were not possible with a general google search. The final
restriction was "peer review,” ensuring articles that were peer-reviewed only.
After removing duplicate articles with the same opioid medication, the database search
results were as follows: PubMed yielded 70 articles, CINAHL yielded 230 articles, and MedLine
yielded 150 articles. While only articles published from 2019 were selected, one article published
in 2016 was selected for its sample size. Most of the results were relevant, hence the need to
apply further restrictions. Ultimately, after thorough consideration, the study selected seven
articles.
Study Selection and Screening Method with Inclusion/Exclusion Criteria
According to Moran et al., the DNP project must include inclusion and exclusion
criteria.21 The current research adopted various aspects of inclusion and exclusion. The exclusion
criteria included articles published before 2019, systematic analysis and meta-analyses, non-peerreviewed, not published in English, unrelated to spinal anesthesia, and studies without
dexmedetomidine as the intervention. Inclusion criteria included randomized controlled studies
(RCTs), peer-reviewed, published from 2019, involve spinal anesthesia, published in English,
involving dexmedetomidine as intervention, and focusing on opioid consumption. Those that
compared the magnitude of sedation and postoperative pain and postoperative events were
included.
Inclusion criteria

Exclusion criteria

Study type

Study type

-

Randomized controlled trials

All studies that are not RCTs (for instance,
meta-analysis, systematic analysis, clinical
trials)

Procedure

Procedure

-

-

Spinal anesthesia

Any procedure not requiring spinal
anesthesia

Intervention

Intervention
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-

Dexmedetomidine as an adjunct therapy

-

All studies not using dexmedetomidine as
an adjunct therapy.

Outcomes

Outcomes

-

-

The magnitude of analgesia and

All studies that do not include adverse

postoperative pain.

events or magnitude of sedation and

-

Adverse events post-operation.

postoperative pain.

-

Focusing on opioid consumption

-

Not focusing on opioid consumption.

Language

Language

-

-

Published in English

Not published in English

State of publication

State of publication

-

-

Peer reviewed

Not peer-reviewed

Year of publication

Year of publication

-

-

2019 and beyond

2018 and below

Table 1: Inclusion and Exclusion Criteria
Collection, Analysis and Data Items
Data were extracted systematically in that information was read from the abstracts and
passed through the inclusion and exclusion criteria. The Johns Hopkins research evidence
appraisal tool was used to critically appraise the studies and quality of evidence (see Polit and
Beck).20 The Johns Hopkins research evidence appraisal tool groups evidence into three cadres of
high quality, good quality, or low quality. High-quality evidence has consistent and generalizable
results and a sufficient sample size 20. Good-quality evidence has reasonably consistent results,
fairly definitive conclusions, and reasonably consistent recommendations. Low-quality evidence
refers to little evidence with inconsistent results.
RESULTS
Study Selection
Three databases, PubMed, CINAHL, and Medline, yielded the most valuable results to
answer the PICOT question. The preliminary search yielded 450 articles distributed
disproportionately across the databases. Fifty duplicates were eliminated, leaving 400 sources for
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screening. The investigators further reviewed the abstracts and removed 307 references, leaving
99 articles for full-text screening. The majority of the studies that were excluded reported lowquality evidence on dexmedetomidine (Dex). Full-text analysis factoring in the
exclusion/inclusion criteria resulted in the exclusion of 92 articles total. Reasons that lead to
exclusion were: articles published before 2019, systematic analysis and meta-analyses, non-peerreviewed, not focusing on opioid consumption, not published in English, dexmedetomidine used
in surgeries not involving spinal anesthesia, and studies without dexmedetomidine as the primary
comparator.
The investigator also curated articles whose results did not reveal dexmedetomidine
benefits, including the reduction of opioid use and postoperative adverse events. In the end, the
studies included were randomized controlled trials as well as studies where Dexmedetomidine
was used as an adjunct therapy in spinal anesthesia, thereby featuring the magnitude of analgesia,
postoperative pain, and reduction of adverse events post-operatively. Therefore, the seven articles
included provided level 1 evidence as appraised by the Johns Hopkins research evidence
appraisal tool.30
The selected articles appropriately answered the PICOT question: “In the surgical
patients undergoing spinal anesthesia (S), how does the use of dexmedetomidine as an anesthetic
adjunct (I), compared to its non-use (C), affect the postoperative (or perioperative) consumption
of opioids (O)?”. The table below summarizes the selected studies:
Author
Ren,

Primary

Study

Sample

Sampling

Publication

Outcome

Design

Size

Method

2019

Chunguang
et al. .

Year of

15

Total

Prospective

86

Purposive

consumption of

RCT

participants

sampling

nimodipine

undergoing

during the first

EITs

48 hr after
surgery
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Shin,

2019

Postoperative

Block

48

Purposive

Hyun-Jung

fentanyl

randomized

participants

sampling

et al. .16

consumption

parallelgroup trial

Sherif,

2019

Abeer A.,

Total morphine

Prospective

150 ASA I

Purposive

consumption

RCT

to III

sampling

and Hazem

patients

E. Elsersy.
"17
Bielka,

2019

Postoperative

A

30 patients

Kateryna,

morphine

randomized, in each

et al. .18

consumption

single-

Purposive
sampling

group

center,
parallelgroup,
placebocontrolled
study
Kang,

2019

Ryung A.,
19

et al.

Time to first

RCT

Sixty-six

Purpose

rescue analgesic

patients

sampling

request

undergoing
arthroscopic
shoulder
surgery

Uusalo,

2019

impact of

RCT

Panu, et

intranasal

al.20

dexmedetomidine

120

Purposive

participants

sampling

57

Purposive

participants

sampling

on postoperative
hemodynamics
and length of stay
Li, Jing, et
al.21

2019

Morphine

RCT

consumption

Table 2: Characteristics of Selected Studies
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Study Characteristics
Cumulatively, the 7 RCTs reviewed had participants n=587 where n= 344 was enrolled
into the control group, and n=243 into the treatment group. The treatment group was subjected to
Dexmedetomidine as an adjunct therapy, and the placebo group had the routine anesthesia
protocols depicting varied drug choices. Patient characteristics, type of surgery, and route of
dexmedetomidine administration differed across the studies. These differences could have an
impact on the generalizability of the study findings. The differences in surgical operations
included: total knee arthroplasty- Shin et al.,23 endovascular interventional therapies- Ren et al.,27
orthoscopic shoulder surgery- Kang et al.,25 laparoscopic cholecystectomy- Bielka et al.,24 lumbar
fusion surgery- Li et al.,28 hip arthroplasty- Uusalo et al.,22 laparoscopic sleeve gastrectomySherif et al.,26. Shin et al.,23, Ren et al.,27, and Kang et al.,25. The differences in routes of
administration included: intravascular,- Li et al. subcutaneous, - Sherif et al.,26 orally (PO), and
intranasally- Uusalo et al.22. These differences are significant factors to consider when analyzing
the magnitude of outcomes.
Patient demographics. All the seven studies reported the recruitment of both males and
females. The age range varied with the youngest subject at 20 years in Shin et al., 23 and the oldest
at 80 years in Uusalo et al.22. Four of the studies selected participants between 35-60. All
participants scheduled for surgery were classified as American Society of Anesthesiologists
(ASA) Physical Status class I through III. All of the studies explicitly stated the type of surgery
involved as well as any inclusion/exclusion criteria. Three of the seven studies discussed
underlying comorbidities including hypertension, diabetes, coronary heart disease, and asthma.
Six of the seven studies included patients with BMI 23—27 while only Bielka et al., 24 worked
with obese patients (defined by World Health Organization (WHO) standards). While the periods
of enrollment differed across studies, the majority of patients were enrolled between 2017-2019.
Hospital demographics. The 7 RCTs were run in hospitals distributed globally. Shin et
al.,23, conducted their study at Seoul National University Bundang Hospital, South Korea. These
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researchers did not provide further details about the hospital. However, in a different study by
Yoo et al., Seoul National University Bundang Hospital is a tertiary university hospital with about
1340 hospital beds and performs at least 12,180 surgeries per year. Ren et al., Kang et al., and Li
et al. did not explicitly state their study settings. However, the Ren et al. study obtained approval
from the Liaocheng People's Hospital (China) institutional review board. Also, Liaocheng
People's Hospital is present in the correspondence.27 Kang et al. study was approved by the
Samsung Medical Center (SMC) Research Ethics Board, Seoul, Korea. The authors either work at
the Department of Anesthesiology and Pain or the Department of Orthopedics at SMC; hence,
this could be the possible study setting.27
Uusalo et al. conducted their study at Turku University hospital in the Salo unit in
southwest Finland. Turku University hospital is one of the largest hospitals in Finland and has
900 beds. The hospital has several branches with no clarity on the number of beds and the total
number of surgeries conducted in said Salo unit. The Li et al. publication correspondence
indicates all the researchers from Honghui Hospital, Xi’an Jiaotong University, Xi’an, Shannxi,
China.28 Bielka et al. conducted their study at the Department of Surgery, and at Anesthesiology
and Intensive Care of the Postgraduate Institute of Bogomolets National Medical University,
Kiev, Ukraine.24 The center conducts about 70000 surgeries annually. Sheriff et al. conducted
their study at Menofa University Hospital, Egypt. The hospital has 400 beds with 13 rooms of
operative theatre.
Methodology and quality. The methodology and interventions consistently varied across
the 7 RCTs. A marked consistency was dexmedetomidine use as an adjunct therapy with controls
using placebo or a sedative of a different class. The studies differed in what they used to induce
anesthesia. Two studies used fentanyl 100 µg, propofol 2.5 mg/kg IV, and rocuronium 0.6 mg/kg
IV26, 24, 1 study propofol (1–2 mg/kg), and cisatracurium (0.2 mg/kg),27 3 studies propofol 2 to 3
ug/mL and remifentanil at 3 to 4 ng/mL,22, 23, 28 and 1 study 1.5 to 2.0 mg/kg propofol and 0.8
mg/kg rocuronium and maintained with inhaled sevoflurane.25 Ren et al. additionally used
Page 17 of 74

sevoflurane (1.5%–2.0%), remifentanil (0.05–0.15 μg/kg/min), and sufentanilfor anesthesia
maintenance.27
All studies differed in the time of dexmedetomidine infusion, including at the induction
of anesthesia in 2 studies,23, 24 10 minutes before anesthesia induction in 1 study,25 five minutes
before anesthesia induction in 1 study,28 and 30 minutes before anesthesia induction in 1 study.22
The majority of the studies administered Dex continuously/as needed until the end of surgery 26, 24,
27

except Shine et al. who stopped infusion 40 minutes following propofol infusion (about the

time they began subcutaneous and skin suture)23 and Kang et al. who stopped after 30 minutes
following initial dex infusion.25 Le et al. and Uusalo et al. did not mention when they stopped dex
infusion.28
Three studies reported using analgesic or pain pre-medications (medications to treat pain
prophylactically). These variances could affect the impact of dexmedetomidine in the end. The
variances included 50 mg of IV dexketoprofen before induction in 1 study,24 preoperative
administration of 1000 mg paracetamol orally in 1 study,22 and preoperative administration of
pregabalin 75 mg PO, celecoxib 200 mg PO, acetaminophen 650 mg PO, and dexamethasone 10
mg IV about 40 minutes before surgery in 1 study.23 However, three studies did not mention
additional pain or analgesic premedication.26, 27, 28 Kang et al. reported restricting premedication
with analgesics/NSAIDs.25
Studies used different doses for initial and continuous Dex therapy and are as follows:
Shin et al. administered a loading dose of 1 μg/kg dexmedetomidine over 10 minutes, then
continuously at a dose of 0.1–0.5 μg/kg/hr.23 Uusalo et al. discussed administration of 50 mg of
Dex intramuscularly (IM);22 Li et al. reported 1 ug/kg of dexmedetomidine given at two doses
subcutaneously;28 Ren et al. reported administration dose of 0.5 μg/kg of Dex for 10 min adjusted
to 0.2–0.6 μg/kg/hr;27 Beika et al. discussed a Dex infusion running at 0.5 μg/kg/hr, beginning at
induction of anesthesia and lasting until extubation; 24 Sherif et al. reported a 1 µg/kg IV Dex
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loading dose over 10 minutes, followed by 0.4 µg/kg/hr of infusion; 26 and Kang et al. mentioned
1.0 mg/kg/hr.
Data collection. Data collected significantly varied across the 7 RCTs. Five studies
measured total morphine consumption as their primary outcome while Sheriff et al., however,
further considered sedation, pain, QOR-40 score, nausea, and vomiting.26 Bielka et al. also
measured duration of hospital stay (LOS), time to first use of rescue analgesia, number of patients
with severe pain, intraoperative fentanyl consumption, time from the end of surgery to extubation,
lengths of intensive care unit (ICU) and general ward stay, degree of postoperative pain 3, 6, 12
and 24 hours after surgery, and incidence of persistent post-surgical pain (6 months after
surgery).24 Unlike Sheriff et al. and Bielka et al., who had an interest in morphine, Ren et al.
measured total sufentanil consumption.27 Ren et al. further studied LOS, pain intensity,
hemodynamics, narcotic and vasoactive prescriptions, the incidence of complications and
symptomatic cerebral vasospasm, patient/physician satisfaction scores, and duration of
postoperative anesthesia care unit (PACU) stay.27 Kang et al. measured time of request of first
rescue analgesia, pain intensity at rest, duration of motor blockade, dexmedetomidine-related
side effects, dexamethasone-related side effects, and total postoperative opioid consumption. 25 Li
et al. further measured cumulative patient-controlled analgesia (PCA) analgesia, VAS at rest,
postoperative nausea and vomiting, delayed wound healing, bradycardia, hypotension, and
cardiac arrhythmia.28 Uusalo et al. measured pharmacodynamics measurements (heart rate (HR)
and mean arterial pressure (MAP)), PACU time and time of discharge, and the total amount of
opioids administered.22 The MAP and HR were collected before surgery, during incision, 1 hour
after anesthesia induction, at the end of the surgery, and 1 hour after surgery.22 Shin et al. studied
the total amount of fentanyl administered via IV PCA 24 and 48 hours postoperatively. Shin et al.
also measured pain scores, amount of rescue analgesics and antiemetics consumed, PACU time,
HR, systolic blood pressure (SBP), and patient satisfaction. These variables were seamlessly
curated to answer the PICOT question.
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Results of Individual Studies and Intervention Effect on the Outcome of Interest
The overall PICOT question aimed to examine how dexmedetomidine as an anesthetic
adjunct affects opioid consumption. While opioid consumption remained the primary goal, it is
pertinent to consider whether dexmedetomidine contributes to a reduction in adverse events and
improvement in beneficial outcomes during surgery. Generally, the project focused on the safe
and effective ways to reduce opioid consumption in surgical units. In this literature review, the
effects of opioid consumption were considered as either a reduction or increase in opioid use. The
review predicted that dexmedetomidine would reduce cumulative opioid consumption. However,
the analysis was not specific to a particular opioid, hence any opioids included in the RCTs were
valid. Side effects or adverse events were defined as undesirable occurrences due to medications
used during surgery. Beneficial outcomes were discussed around the time of first use of rescue
analgesia, reduction in pain, and better quality of life.
Effects on cumulative opioid consumption: All the 7 RCTs reported that Dex given in
any approach reduces cumulative opioid consumption. Sheriff et al. demonstrated that
dexmedetomidine given at 1 µg/kg IV loading dose over 10 minutes, followed by 0.4 µg/kg/h
reduces total morphine consumption by at least 35%.26 These authors learned that the group that
was not exposed to dexmedetomidine (group L and C) had higher consumption of morphine,
including 18±4 and 29±5 mg compared to group D, which had a morphine consumption at 14±4.
Like other studies, Shin et al. shows that Dex significantly reduced postoperative total fentanyl
consumption via IV PCA.23 Uusalo et al. established that including Dex as adjunct therapy
reduced cumulative opioid consumption. The cumulative morphine requirement in the Dex group
was low, 152 mg, compared to 178 mg in the control group. 22 Uusalo et al.’s findings are
interesting in that Dex was administered intranasally. Li et al. proved that subcutaneous
dexmedetomidine, can lower cumulative opioid consumption as well. In this study, cumulative
opioid consumption was low at 7.6 mg in the Dex group compared to 16 mg in the control group.
Sheriff et al., Shin et al., Li et al., Uusalo et al., and Kang et al. demonstrated that Dex can be
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infused before induction and still affect opioid consumption postoperatively. In 2018, Bielka et al.
proved, that dexmedetomidine as adjunct therapy contributes to postoperative morphine
consumption reduction.24 Bielka et al. observed that the treatment group consumed 5 mg of
morphine over 24 hours compared to 15mg in 24 hours in the control group. Ren et al. made their
case that dexmedetomidine at a loading dose of 0.5 μg/kg for 10 min, adjusted to 0.6 μg/kg/hr
during surgery reduces cumulative consumption of sevoflurane, remifentanil, and sufentanil
within 48 hours of surgery. Cumulative opioid consumption was low in Kang et al. study where
the dexmedetomidine group had median consumption of 18.9 mg compared to the two “controls”
D1 at 27.1 mg and real control group at 39.9 mg.27 Generally, given in any route as defined by
surgery type, Dex is effective in reducing cumulative opioid consumption.
Possibility of adverse events: Respiratory complications were lowest in the dex group
(1/49) than controls 5/49 and 2/49 in the Sherif et al. study.26 There were also reduced incidences
of nausea, vomiting, hypertension and tachycardia in Sherif et al., Kang et al., Li et al., and
Bielka et al. studies.26,25,24 Ren et al. and Uusalo et al. did not report any adverse events of interest
to the literature review. There was no statistical difference in these adverse events in the Shin et
al. study.23
Potential benefits: Most studies reported a decrease in post-operative pain. Bielka et al.
reported the incidence of severe postoperative pain as 1(3) in the Dex group and 7(23) in the
control group, the number in parenthesis signifying 25-75% interquartile ranges. 24 Sherriff et al.
and Ren et al. reported decreased pain intensity at all-time points, including 8, 24, and 48 hours
from the emergence of anesthesia. In Li et al., the VAS score was low (highest score1.5)
compared to the highest score of 4 in the control group. The time to first rescue analgesic request
was also prolonged across studies as follows: Bielka et al. up to 180 minutes, Kang et al. 66.3
hours, and Li et al. 10.5 hours.23,25,28 Ren et al. found no statistical difference in the time of
request of rescue analgesia, while Shin et al. were not interested in such findings.
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Risk of Bias
Bias arising from the randomization process: All the 7 RCTs solved this bias and
lowered the risk of selection bias. Selection bias is often minimized when the allocation sequence
is random and adequately concealed, and when baseline characteristics are integrated into the
process.35 Four studies reported using computer algorithms, such as research randomizer (Sheriff
et al.), computer algorithm (Bielka et al.), computer‐generated randomization table/sequence (Ren
et al., Kang et al., Li et al.), and web-based randomization system (Shin et al.).26,24,27,25,28,23 Uusalo
et al. were not clear about their randomization protocol despite the study being an RCT.
Bias due to missing outcome data: The risk of attrition bias in the Shin et al. study is
high. According to Shin et al., 54 participants were enrolled in the study and distributed into two
groups.23 However, only 48 participants completed the study.23 There are several uncertainties as
to the reasons for such a change. Participants withdrawing from the study, participants' data
record lost, or participants no longer experiencing the outcome due to death can lead to missing
measurements and cause bias in estimating the intervention effect.35 The other six studies have a
low risk of attrition bias.
Bias in measurement of the outcome: This bias was significantly low because most
studies blinded outcome assessors. Blinding reduces the risk of under-ascertainment/overascertainment. The potential for this bias cannot be ignored because it affects the intervention's
estimates.35 Across the 7 RCTs, the authors reported blinding outcome assessors. 24,25,28,23 Ren et
al., Sheriff et al., and Uusalo et al. were not clear about blinding the investigators.
Unintended Consequences
Positive
Even though the primary aim was total opioid consumption reduction, dexmedetomidine
is beneficial in other unprecedented ways. In the Shin et al. and Kang et al. studies, patients in the
dexmedetomidine group recorded more satisfaction with the quality of post-operative
analgesia.23,25 Including Dexmedetomidine can also reduce the need for NSAIDs as established in
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the Uusalo et al. study.22 Other potential benefits include improved quality of sleep, shorter
recovery time in PACU, lower LOS, improved surgeon satisfaction score, and higher QOR-40
scores.27,24,26,25 Anesthesia providers working in surgical units can always leverage these benefits.
Negative
Like other pain management drugs, dexmedetomidine has been associated with adverse
events. Shin et al. recorded bradycardia and hypotension in their study. 23 These authors also
attempt to link the increased systolic blood pressure (SBP) due to Dex with α2B action in the
postsynaptic cells.23 Regardless of the veracity of the hypothesis, such adverse events are worth
monitoring during surgery. Perineal pruritus upon infusion is also possible, according to the Kang
et al. study.25 However, this event may resolve within 48 hours and tend not to have any
detrimental effects in the end. According to Ren et al. study, dexmedetomidine at an initial dose
of 0.5 μg/kg for 10 min adjusted to 0.2 μg/kg/hr throughout the surgery may cause symptomatic
cerebral vasospasm.27 Even though these events were not consistent across other studies (some
studies did not report any statistically different adverse event), they should not be underestimated
during surgery.
Limitations of the Literature Review
-

There were significant variances across the studies, including presence or absence of
premedication with analgesics. While three studies included NSAIDs/analgesia, 24,22,23
three studies did not mention prophylactic pain control 26,27,28 and one study eliminated
these drugs.25 Upon comparison of all of the studies, it was determined that there was a
lack of uniformity in premedication.

-

There was a lack of uniformity in the initiation and continuous dose of Dex as well. This
limitation makes it challenging to generalize a particular dose.

-

There was heterogeneity in initiating Dex as an adjunct therapy. While some studies
infused Dex before induction, 26,23,28,22,25 others administered the medication at the point
of anesthesia induction. 27,24
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-

There was no uniformity on the route of Dex delivery. Route of delivery is crucial to drug
metabolism as some administration routes allow the drug to exert its effects quicker than
others.

Recommendations
The strategic plan aimed at compelling anesthesia teams is to focus on tactics that reduce
opioid consumption. Given this perspective, the literature review recommends the following:
-

Five studies established dexmedetomidine before anesthesia induction to reduce
cumulative opioid consumption.26,23,28,22,25 Dex can be introduced 5, 10, or 30 minutes
before induction.

-

Dex can be effective when administered at the time of anesthesia induction.27,24

-

Dex can reduce cumulative opioid use whether given as a loading and adjusted dose, or a
single shot throughout the surgery. Three studies have confirmed loading dose of 0.5
μg/kg-1 μg/kg dexmedetomidine administered over 10 minutes, then administered
continuously at a dose of 0.1–0.5 μg/kg/hr.23,26 Two studies have confirmed 0.5 μg/kg/h1.0 mg kg-1 throughout the surgery.24,25

-

The route of Dex delivery should not be a barrier to prescription. Five studies have shown
Dex can be effective through IV administration.23,24,25,26,27 One study has shown benefits
of low-dose Dex intranasally22 and one study has shown benefits when delivered
subcutaneously.28

DISCUSSION
Summary of Evidence
The study yielded seven RCTs with a total of 587 participants where n= 344 was enrolled into the
control group and n=243 into the treatment group. 437 articles were excluded based on systematic
exclusion/inclusion criteria that excluded duplicates, articles published before 2019, studies,
meta-analyses and systematic reviews, and studies that did not center on dexmedetomidine.
Randomized controlled trials (RCTs) and articles that focused on the reduction of opioid
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consumption were included in the systematic review thereby providing level I evidence. Studies
were considered level I evidence if they satisfied all the aforementioned items, including random
sequence generation, allocation concealment, intent-to-treat analysis, blind or independent
assessment for important outcomes, co-interventions applied equally, F/U rate of 80%+, and
adequate sample size.34 All studies had a rigorous approach to their findings; the methodologies
are reproducible and believable. The 7 RCTs were graded as level I (low-risk bias) evidence
following a critical appraisal using the John Hopkin's appraisal scale and Grades of
Recommendation Assessment, Development and Evaluation (GRADE) schematic developed by
the Agency for Healthcare Research and Quality (AHRQ).34 The level of recommendation used in
this study follows the Berkman et al. outline for i) high, ii) moderate, iii) low, and iv) insufficient
levels of recommendation.35 The recommendations can be translated as i) high (A)- very
confident on the estimated effect for this outcome”, ii) moderate (B)- moderately confident on the
estimated effect for this outcome, iii) low (C)- Limited confidence on the estimated effect for this
outcome”, and iv) insufficient (D)- No evidence and ability to estimate the effect for this
outcome.35 The evidence is summarized below:
i.) All studies reported a significant decrease in opioid consumption when dexmedetomidine
was administered as an adjunct therapy22,23,24,25,26, 27, The timing of administration did not
influence this outcome.
ii.) Three studies established that dexmedetomidine at the induction of anesthesia reduces
cumulative opioid consumption. 23, 24,27
iii.) Other studies established a reduction in opioid consumption when Dex was administered
10 minutes,25 five minutes,28 and 30 minutes,22 before induction of anesthesia.
iv.) Three studies found a loading dose of 0.5 μg/kg-1 μg/kg dexmedetomidine administered
over 10 minutes, then administered continuously at a dose of 0.1–0.5 μg/kg/hr to reduce
overall opioid consumption.23,26
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v.) Two studies found that a dex dose of 0.5 μg/kg/h-1.0 mg kg-1 throughout the surgery
reduced cumulative opioid consumption24,25
vi.) One study found that intranasal Dex reduces cumulative opioid consumption. 28
Limitations of the Study
One minor limitation of the study is the restriction to articles that date from 2019. To this
end, bias could exist if earlier rigorous studies reported no effect of Dex on opioid consumption.
However, the fact that studies used are updated address such a limitation.
One major limitation of the literature review was heterogeneity in the methodology. This
review cannot debate precisely about the standard dose and time of administration of Dex. The
RCT differed about these issues. For instance, when one study used a loading dose of 1 μg/kg
dexmedetomidine over 10 minutes, followed by a continuous infusion of 0.1–0.5 μg·kg-1·hour-1,
another study used 0.5 μg/kg/h DEX infusion throughout the surgical process.23,24 The trend was
consistent throughout the RCTs. Therefore, this study cannot generate a standardized approach to
dosing Dex. The studies also differed in their time of induction. While three studies administered
Dex at induction,23, 24,27 four studies administered the medication before induction with a further
difference like 528, 10,25, and 3022 minutes before induction. Even though the core result is
similar, such differences limit the generalizability of the standard time for Dex administration.
Additionally, anesthesia used was also a significant variable across the studies. Studies differed
on the choice and dose of anesthesia. Two studies combined fentanyl, propofol and rocuronium,
26, 24

one study combined propofol and cisatracurium,27 three studies combined propofol and

remifentanil,22, 23, 28 and one study used propofol and rocuronium and maintained with inhaled
sevoflurane.25 These differences challenge the discussion about which combinations could yield
optimal outcomes.
There was heterogeneity about premedication with analgesia/NSAIDs. Kang et al.
clarified about restricting premedication with analgesics/NSAIDs. 25 Their approach differed from
Bielka et al. who premedicated with 50 mg of IV dexketoprofen,24 Uusalo et al. with 1000 mg
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paracetamol orally,22 and Shin et al. with pregabalin 75 mg PO, celecoxib 200 mg PO,
acetaminophen 650 mg PO, and dexamethasone 10 mg IV.23 Premedication with non-opioid
analgesics reduce the consumption of opioid analgesics as demonstrated in many studies.
Therefore, there is a possibility of premedication with analgesics as a confounder. Such variances
distort the discussion about whether Dex should be prescribed with or without non-opioid
premedication. This literature review may fail to account for many of the covariates mentioned
above and could confound the findings.
All the RCTs cannot be generalized. Even though the studies differ on the surgical
procedure, they all report using a single unit/center. No study reported using a multicenter
approach. Therefore, it is not definite that the results can be replicated in all settings. The studies
also worked with small sample sizes. This may be largely due to the number of surgeries
conducted in a certain time frame. Small sample size and focus on a single-center reduce the
chances of generalization. However, the geographical diversity of the studies may address
generalizability. The studies report similar trends in outcomes from different geographical
regions, including Asia and Africa. Therefore, there is consistency.

Recommendations for Future Research
Future studies should address the generalizability of the findings. There is a need to
consider multicenter RCTs with large sample sizes.37 The current studies were deficient in these
areas. Even though one study compared different doses of Dex, the comparison was not sufficient
in judging the optimal dose of administration. The studies were not homogenous in their dex
doses; this is a potential gap that could affect practice. Ideally, Dex shows a dose-dependence
relationship, where large doses cause deep sedation and cardiovascular effects. 38 Future studies
are warranted to compare optimal doses of Dex against associated adverse events. For instance,
future studies need to compare the optimal effect of using 0.5 μg/kg/h dex throughout the study
starting with a loading dose of 1 μg/kg dexmedetomidine over 10 minutes, followed by a
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continuous infusion of 0.1–0.5 μg·kg-1·hour-1. Studies comparing different dex doses should
also measure plasma concentrations. None of the RCTs measured plasma concentrations despite
the possibility of such values influencing practice. Ideally, Dex shows a dose-dependent
relationship.38 Different doses produce different plasma concentrations. Therefore, there is a
possibility of variance in effective dex concentration.
Besides investigations on the optimal dose of Dex, future studies should clarify the
necessity for premedication with analgesics/NSAIDs when using Dex as an adjunct therapy.
There are conflicting views on this issue. For instance, Kang et al. excluded NSAIDs/analgesia
from their methodology. In this study, patient satisfaction with pain management within 24 hours
was high in both the control and treatment groups.25 Three other studies, Bielka et al., Uusalo et
al., and Shine et al., mentioned using NSAIDs/analgesia in their methodology. 22,22,24 Among these
two approaches, there is no clarification of the best standard of care in anesthesia practice.
Studies should evaluate the magnitude of pain on the inclusion or exclusion of premedication
NSAIDs/analgesics.
Also, future studies should investigate Dex's implication in pediatric surgery. The current
RCTs were strongly biased towards the adult population; the results remain irrelevant in the
pediatric population. Like adults, children and adolescents have also been prescribed opioids
after, and the youths have an increased risk of opioids misuse after surgery. 39 According to
Cardona-Grau et al., clinicians can reduce opioid prescription in the pediatric population without
increasing pain scores. Dex could be a possible route; however, current studies cannot answer the
feasibility and outcomes in this population. Studies already allude to better outcomes like
stabilization of the circulatory system, better stress response, reduction in restlessness, pain, and
reduced psychomotor agitation.41,42 These outcomes set a precedence that Dex could safely and
effectively reduce opioid consumption in the pediatric community.
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Recommendations for Practice
Opioid use has been a source of undesirable events as a result of surgery. Some of the
commonly reported consequences including opioid use and misuse, hyperalgesia, and respiratory
distress. Several approaches have been proposed to reduce opioid consumption throughout the
perioperative period, and the majority of the proposals are yet to be confirmed. Nonetheless,
dexmedetomidine has proven to reduce opioid consumption perioperatively and has possibly
changed the opioid narrative. Nurses, clinicians and anesthesia providers involved in surgical
procedures should rely on evidence-based proposals in mitigating the consequences of opioids.
Recommendations (evidence-based) that should guide the use of dexmedetomidine as an
adjunction therapy to reduce opioid consumption include:
i.) Administration of dexmedetomidine (Dex) before induction of anesthesia (Level I
evidence, Grade A recommendation). Clinicians can administer Dex five minutes (Level
I evidence, Grade C recommendation), 10 minutes (Level I evidence, Grade C
recommendation), or 30 minutes (Level I evidence, Grade C recommendation) before
surgery.
ii.) Administration of Dex at the induction of anesthesia (Level I evidence, Grade A
recommendation).
iii.) Administration of Dex intranasally (Level I evidence, Grade C recommendation).
iv.) Starting Dex at a loading dose of 0.5 μg/kg-1 μg/kg dexmedetomidine administered over
10 minutes, then administered continuously at a dose of 0.1–0.5 μg/kg/hr (Level I
evidence, Grade A recommendation).
v.) Starting Dex at 0.5 μg/kg/h-1.0 mg kg-1 and maintaining this dosage throughout the
surgery (Level I evidence, Grade B recommendation).
The following flow diagram is a proposed algorithm based on current evidence:
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Figure 1: Reduction in opioid consumption with dexmedetomidine as adjunct therapy during
surgery
Conclusions
After a rigorous appraisal of seven RCTs, empirical evidence determined that
dexmedetomidine infused at varying doses and periods reduces the consumption of opioids
during and after surgery. The systematic review established that a loading dose of 0.5 μg/kg-1
μg/kg dexmedetomidine for ten minutes followed by a continuous dose of 0.1–0.5 μg/kg/hr or a
starting and continuous dose of 0.5 μg/kg/h-1.0 mg kg-1 reduce opioid consumption. The review
also determined that 50 mg Dex intranasal has a similar effect. However, this study has made no
determinations on side effects of using or not using Dex as an adjunct therapy during surgery.
Given the findings, clinicians can use the algorithm provided to change surgical
modalities. The algorithm proposed is a synthesis of the underlying evidence and is capable of
reducing opioid consumption. Healthcare providers should have a patient-specific approach since
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the algorithm offer multiple viable options. Notwithstanding, the inclusion of Dex as an adjunct
therapy reduces opioid consumption during surgery.

IMPLEMENTATION
Setting and Participants
The setting will take place via an online survey and a PowerPoint educational module
with alumni of Florida International University’s (FIU) Nurse Anesthesia Program. The study
will include Certified Registered Nurse Anesthetist (CRNAs). The participation will be based on
individuals within an email list that is provided by FIU faculty. These individuals will be asked to
provide feedback regarding the educational module's anesthesia providers' experience. The
anticipated sample size will be between 10-15 participants.
Recruitment
The target population consisted of CRNAs who have taken care of patients receiving
spinal anesthesia. Participants were acquired through an email list provided by FIU faculty. The
anesthesia providers recorded on the email list were sent an email containing an invitation along
with a link to participate in the educational module.

Description of Approach and Project Procedures
The primary methodology of the proposed project is to have the survey taker participate
in an online Zoom educational module that focuses on the perioperative management of patients
receiving dexmedetomidine during spinal anesthesia. The project will be implemented by
conducting an online pre-test survey that will assess the anesthesia provider’s knowledge about
utilizing dexmedetomidine in a patient receiving spinal anesthesia and its effects during the
perioperative period. The existing knowledge and baseline understanding of the anesthesia
provider will be analyzed using a pre-evaluation tool that will subcategorize information
regarding the impact of the intervention and determine its significance
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The second segment will include a Zoom educational PowerPoint. The primary means of
learning will be through a voiceover PowerPoint presentation with information regarding the
utilization of dexmedetomidine in a patient receiving spinal anesthesia and its effects during the
perioperative period. Understanding anesthesia providers' current level of education is essential in
bridging existing gaps in knowledge and supporting the need for additional tools to ensure
patients receiving dexmedetomidine during spinal anesthesia are receiving evidence-based care
during the perioperative period. Viewing the presentation will offer insight and perspective for
anesthesia providers regarding the importance of reducing opioid consumption by utilizing
dexmedetomidine during the administration of spinal anesthesia. The observed and documented
evidence backs an evidence-based project with inclusive information regarding utilization of
dexmedetomidine in the patient receiving spinal anesthesia and its significance in reducing opioid
requirements.
The third segment of the project will contain an online post-assessment test to determine
if the CRNAs participating in the module achieved the learning objectives as well as examine
perception to the intervention and the contents that were delivered. This data will provide useful
feedback regarding the impact of the educational intervention and will determine how to further
progression in expanding the use of dexmedetomidine in spinal anesthesia. The post-test results
will provide applicable information regarding the effectiveness of the module and willingness of
the anesthesia provider concerning administration of dexmedetomidine during spinal anesthesia
and reduction of the need of rescue opioid administration perioperatively.

Protection of Human Subjects
CRNAs participating in the survey remained anonymous and the data was secured via
utilization of randomized code identifiers. The electronic data collected from both the pre- and
post-test were protected by a laptop locked with a password. Using laptop passwords as well as
spyware safeguarded the security of the information. There are no identifiable risks to the study
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as the only requirement is the time allotted by each CRNA in the educational module which took
approximately less than 20 minutes to finish.
Data collection and analysis
The study involves administration of a pretest and a posttest to decipher the educational
module’s impression. The pre- and posttest were conducted using Qualtrics as the survey
platform to determine if participants have an understanding of handling surgical patients
receiving spinal anesthesia and dexmedetomidine throughout the perioperative period. The survey
had a total of 10 questions that focus on knowledge surrounding the opioid epidemic and
applying opioid-sparing methods in practice. The pre-test survey will measure the practitioner’s
basic knowledge on the subject at hand. The post-test survey will interpret the participants
knowledge obtained from the educational presentation as well as application of said knowledge to
professional practice. Any data collected will be strictly confidential in that no subject identifiers
will be recorded throughout the duration of the study.
Data Management and Measure
The investigator of the project will be the DNP student responsible for acquiring FIU
alumni via an email list for participation in the educational module. Each response will be
recorded to evaluate the survey taker’s knowledge base before watching the PowerPoint and after
to identify if learning has occurred. No personal identifiers will be recorded for any of the study
participants so that anonymity will be maintained. The ramifications of the educational module
will be determined upon receiving the results of the pre- and post-test. A thorough analysis of the
study should reveal evidence that will be utilized to interpret the efficacy of the educational
module and if the CRNA’s knowledge has been enhanced. The co-investigator on this project will
also store any data obtained from participants in a password-protected laptop computer.
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IMPLEMENTATION RESULTS
Pre/Post-Test Demographics
The pre-test demographics are shown in Table 3., shown below.
Demographic
Total Participants
Gender
Male
Female
Age
18-25
26-40
41-55
>55
Ethnicity
Hispanic
Caucasian
African American
Asian
Other
Years of Experience
1 to 2 years
2 to 5 years
5 to 10
More than 10 years

n (%)
10 (100%)
3 (30%)
7 (70%)
0 (0%)
7 (70%)
2 (20%)
1 (10%)
5 (50%)
3 (30%)
0 (0%)
0 (0%)
2 (20%)
2 (20%)
5 (50%)
2 (20%)
1 (10%)

A total of 10 CRNAs participated in the pretest demographic section. The majority of the
participants were female (n=7, 70%) as opposed to male (n=3, 30%). A variety of ethnicities were
represented in this group: Caucasian (n=3, 30%), Hispanic (n=5, 50%), and other (n=2, 20%).
The participants were questioned about the amount of time in years that they have been practicing
anesthesia and the findings ranged: 1 to 2 years (n=1, 20%), 2 to 5 years (n=2, 40%), 5 to 10
years (n=2, 20%) and more than 10 years (n=1, 10%). The survey takers comprised of DNPprepared CRNAs (n=7, 70%) as well as Master level prepared CRNAS (n=3, 30%).
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Pre-Test Likelihood of Utilization of Dexmedetomidine in Patients Receiving Spinal
Anesthesia
The pre-test contained information regarding the perioperative management of surgical
patients receiving dexmedetomidine as an anesthetic adjunct in spinal anesthesia. The majority of
participants (n=7, 70%) stated that they were unlikely to utilize dexmedetomidine in spinal
anesthesia. The survey concluded that most respondents (n=7, 70%) were unaware of the exact
prevalence of the opioid epidemic. This group of participants admitted to not knowing that the
use of dexmedetomidine in spinal anesthesia reduced opioid consumption by 35%.

Pre-Test Identification of Current Knowledge about Perioperative Management of Surgical
Patients Receiving Dexmedetomidine as an Anesthetic Adjunct to Spinal Anesthesia
The survey focuses on identifying the benefits of utilization of dexmedetomidine as an
anesthetic adjunct in spinal anesthesia. The majority of the participants understood the
mechanism of action of dexmedetomidine; the question was correctly answered by 9 participants
(n=9, 90%). When asked about the benefits of dexmedetomidine use, all 10 participants answered
the questions correctly (n=10, 100%). All participants (n=10, 100%) answered correctly when
questioned about dexmedetomidine’s side effect profile. The participant's scores improved in the
post-test when asked about questions pertaining to opioid related deaths (n=10, 100%). The
participants were asked questions involving the prevalence of opioid misuse and the side effects
of opioids. Their scores showed a universal improvement upon comparison of the pre-and postsurvey. Table 4 shows the difference in responses from the pre- to post-test.
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Table 4. Difference in Pre- and Post-Test Knowledge
Questions
6% of previously opioid naïve surgical patients continued taking opioids
approximately how long post-surgery?
What do the adverse effects of chronic opioid consumption include?
In 2018, how many Americans reported 12 years and older partook in the
misuse of opioids?
Since 1999, how many Americans have died from an opioid overdose?
On what receptor does Dexmedetomidine exert its action?
What do the benefits of Dexmedetomidine include?
What are some of the side effects of Dexmedetomidine?
Dexmedetomidine given at 1 µg/kg IV loading dose over 10 minutes,
followed by 0.4 µg/kg/h reduces total morphine consumption by at
least____.
How likely are you to use dexmedetomidine as an anesthetic adjunct in
patients receiving spinal anesthesia?
How likely are you to recommend utilizing dexmedetomidine as an
anesthetic adjunct in patients receiving spinal anesthesia?

Pretest
50%

Posttest
100%

Difference
50%

100%
60%

100%
90%

0%
30%

40%
100%

80%
100%

20%
0%

100%
100%
70%

100%
100%
100%

0%
0%
30%

40%

50%

10%

40%

50%

10%

On average, the scores on the post-test increased compared to that of the pre-test after the
participants viewed the online PowerPoint presentation. All of participants improved knowledge
about the prevalence of the opioid epidemic and the importance of decreasing opioid used when
possible (n=10, 100%). The majority of respondents report improved knowledge about
perioperative management of patients receiving dexmedetomidine during spinal anesthesia (n=7,
70%). When asked questions dexmedetomidine regarding mechanism of action, benefits of use as
well as side effects, there was no decipherable proof of learning as all the participants answered
these questions correctly on the pre- and post-test (n=10, 100%) There was an increase in
understanding how much the consumption of opioids decreases upon incorporation of
dexmedetomidine in the anesthetic plan of care (n=3, 30%). Lastly, half of the participants in the
post-test stated they would be likely to use and/or recommend dexmedetomidine as an anesthetic
adjunct in patients receiving spinal anesthesia (n=5, 50%).
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Post-Test Likelihood of Utilization of Dexmedetomidine in Patients Receiving Spinal
Anesthesia
A minority of the participants stated they were somewhat unlikely to utilize
dexmedetomidine in patients receiving spinal anesthesia in the pretest (n=4, 40%). The post-test
showed that one participant changed their answer from “somewhat unlikely” to “somewhat
likely” (n=1, 10%). A minority of the participants stated they were somewhat unlikely to
recommend utilization of dexmedetomidine in patients receiving spinal anesthesia in the pretest
(n=4, 40%). The post-test displayed that one participant also changed their answer from
“somewhat unlikely” to “somewhat likely” (n=1, 10%).
Summary
Overall, the results displayed improvement in knowledge upon evaluating the scores of
the pre-test and post-test. The average knowledge gain was a total of 15%. The post-test exhibited
that participants are somewhat likely (n=5, 50%) to utilize dexmedetomidine as an anesthetic
adjunct in patients receiving spinal anesthesia.

Summary
100
90
80
70
60
50
40
30
20
10
0
Knowledge

Will Use/Recommend Utilization of
Dexmedetomidine as an Anesthetic Adjunct in
Patients Receiving Spinal Anesthesia
Pre-test

Post-test
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IMPLEMENTATION DISCUSSION
Limitations
One of the limitations of the study was a small sample size; the survey was emailed to
alumni of FIU’s Nurse Anesthesia Program. The email list contained 61 CRNAs, however only
ten people responded to the survey. A greater sample size is ideal to augment the study's findings
and offer a sample size that is representative FIU’s graduated anesthesia practitioners. The survey
link, which consisted of a pre-test that included demographics questions, a voice-over PowerPoint
lecture, and a post-test, was available to the respondent for two weeks; it is possible that
lengthening the time of survey availability may have produced more responses. Lastly, the study
was executed completely online, preventing it from being distributed through other modalities.
Future Implications for Anesthesia Practice
The literature demonstrated that Dex given in any approach reduces cumulative opioid
consumption. Bringing the insight that total morphine consumption is decreased by at least 35% 26
when utilizing dexmedetomidine in spinal anesthesia can help encourage its use by anesthesia
providers. Even though the primary aim was total opioid consumption reduction, it was
discovered that dexmedetomidine is beneficial in that patients receiving dexmedetomidine during
spinal anesthesia reported more satisfaction with the quality of post-operative analgesia. 23,25
Incorporation of Dexmedetomidine has also reduced the need for NSAIDs, improved quality of
sleep, and exhibited a shorter recovery time in PACU 22, 27,24.
Heavy reliance on opioid use has been a cause of undesirable occurrences in the
perioperative period, including opioid abuse, hyperalgesia, and respiratory distress.
Dexmedetomidine has been proven to reduce opioid consumption perioperatively in patients
receiving spinal anesthesia and can possibly change opioid perceptions. This study displays that
anesthesia providers involved in surgical procedures should rely on evidence-based applications
in modifying the consequences of opioids. The quality improvement project showed that the
intervention of brining awareness to these factors was effective in increasing healthcare providers
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knowledge and increased the likelihood of utilizing/recommendation of dexmedetomidine as an
anesthetic adjunct in patients receiving spinal anesthesia.
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Appendix A: Prisma Flow Diagram

Figure 3: PRISMA Flow diagram

DNP Project Action Plan and SWOT Analysis
Primary Aim
Opioids constitute the biggest share of analgesics used in surgical units throughout the
US. Most surgical patients are prescribed opioids perioperatively. 1 In reality, patients have
benefited significantly from prescribed opioids. The rapid onset of action, lack of analgesic
ceiling- dose (beyond which there is no additional pain relief), and consistent relief of postsurgical pain have increased their preference among surgeons, nurses, and patients. 1 While the
benefits remain at the forefront, the adverse events have raised significant concerns among
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surgical teams. The use of opioids in surgical units has been noted to significantly impact the
opioids crisis, which has led to many deaths.5,4,7,9 Surgical units have also witnessed higher rates
of opioid-induced endocrinopathy, hyperalgesia, urinary retention, postoperative respiratory
depression, bradycardia, somnolence, nausea, vomiting, and rash.10.12 These occurrences have the
potential to increase medical costs and lead to poor outcomes. Therefore, there is a need to reduce
opioid consumption in surgical units with adjuncts like dexmedetomidine.
The primary aim of the DNP project is to reduce the current opioid dosages being used as
analgesic therapies during surgeries by incorporating dexmedetomidine. Some of the opioids this
intervention aims to reduce throughout the perioperative period include morphine,
hydromorphone, fentanyl, oxycodone, oxymorphone, and tramadol. Well-executed studies have
demonstrated that dexmedetomidine has the potential to help reduce opioid requirements and
produce better effects overall. These include studies that show that dexmedetomidine infusion at
an initial dose of 0.5-1 μg/kg with 0.11- 0.6 µg/kg-1 hr-1 dose adjustment reduces perioperative
opioid consumption, time of first analgesia demand, reduction in VAS score, and fewer adverse
events.27,23,2624,2513,22 These studies also show that dexmedetomidine is not associated with
increased occurrence of nausea, vomiting, and respiratory distress. Surgical teams, therefore,
ought to adopt this novel adjunct therapy for various surgical procedures.
Goals and Outcomes
Sufficient evidence underscores the inclusion of dexmedetomidine in the anesthetic plan
and has the potential for better analgesic effects than the sole use of opioids. It is prudent for
surgical teams to understand the urgency of reinventing current opioid practice by incorporating a
comparable and safe option. The goals and outcomes described below are Specific, Measurable,
Attainable, Realistic, and Time-specific (SMART). These SMART goals emphasize tangible
outcomes and improve the skills, knowledge, and attitude of members of the surgical team. 28
Moreover, the outcomes are measurable and congruent with a timeline.
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Figure 3: SMART Goals

Strength, Weakness, Opportunities, and Threats (SWOT) Analysis
The SWOT analysis involves discussing factors that could impact the DNP project's
implementation and success or failures. The process analyzes the surgical unit’s strengths (S),
weaknesses (W), opportunities (O), and threats (T) to achieving organizational goals and desires
outcomes.30 Briefly, analysis of the surgical unit’s strengths involves reflection about what the
facility does well and its unique resources. Weaknesses are factors that the surgical unit could
improve, especially in instances where resources are lacking. Opportunities are what the surgical
facility could leverage to improve the unit’s position to effect change. Finally, potential threats
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may be underlying issues that can prove harmful to the project. Analyzing the above items allows
the DNP project implementation team to establish itself in an environment that cannot be easily
displaced by opposing factors.31 Table 4 below provides a matrix of the SWOT analysis that
could impact the implementation of the DNP project as well as its aim, goals, and objective.

Table 5. SWOT Matrix
STRENGTHS (+)










WEAKNESSES (-)

The surgical unit has a good reputation
for evidence-based practice (EBP). The
evidence-based team has a good history
of ensuring quality improvement
proposals are well accepted and run.
Over the past few months, members of
surgical teams within the facility had
begun registering the challenges with
opioid use during surgery. The project
will, therefore, provide a sense of relief.
Reducing opioid prescriptions by the
addition of dexmedetomidine will not
involve an additional cost. Technically,
costs will be cut.
OPPORTUNITIES (+)
The healthcare facility plans to hire new
healthcare professionals. This could be a
chance to propose the recruitment of
specialists in surgery.
While dissatisfaction has been reported
with dexmedetomidine use, healthcare
professionals have expressed concerns
about opioid side effects.







Healthcare professionals working in
surgical units have in the past expressed
dissatisfaction with dexmedetomidine.
The surgical team is often poorly
staffed. Training these professionals is
unlikely to be seamless.

THREATS (-)
While dexmedetomidine may be safe
compared to opioids, the adverse effects
cannot be ignored.

Quality Improvement Project Details and Rationale
The quality improvement model will be based on the revised Iowa model for evidence-based
practice to promote healthcare excellence. The Iowa model comprises seven steps that clinicians
can use to implement change. The first step is to identify triggering issues and opportunities. This
step involves questioning current practice and is highly motivated by patient outcomes. 32 In the
context of the DNP project, this step involves realizing the impact of opioids in surgical units and
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the need to identify alternatives. The next step in the Iowa model is to state the question and
reframe it in the PICOT format.32 Stating the question determines boundaries for change and
provide a bearing to the evidence-based practice team. Once clinical questions have been
formulated, the third stage in the Iowa model is to assign priority to each question. This model
proposes that not all questions can be solved through the EBP process. 32 The model further
proposes that high-priority should be assigned to topics related to patient safety, high-cost, or
high-risk patients.32 Low priority topics that do not align with the organization's mission and
goals often do not attract resources. The project leader has accomplished these first three steps.
The next step in the Iowa model is to form an EBP team. Selecting the EBP team should reflect
on interprofessional involvement and the skills required by the project for implementation and
evaluation.33 To this end, the EBP team for the DNP project will include the chief nurse of the
surgical units, head of CRNAs, head of surgery, the medical director, nurse administrator, and
nurses assigned to the emergency department. This team will perform the rest of the tasks within
the model. The nurse administrator will be included as an ex-officio member to lobby for
resources and petition for additional healthcare professionals in the coming recruitment initiative.
The next step in the Iowa model is to assemble, appraise, and synthesize the body of evidence. 32,33
This step has been partly accomplished. The EBP team will appraise and synthesize the body of
evidence already assembled. The team will grade the evidence from high-quality to low-quality.
Upon review of the available evidence, the team will determine whether the amount of evidence
collected will be sufficient.32,33 Insufficient evidence will prompt the team to look further with the
help of the librarian. When an adequate amount of evidence is gathered, the EBP team will move
to the next stage to design and pilot practice change. Piloting involves controlled environments,
which allows the EBP team to evaluate whether there is a difference with the placebo. 32 To this
end, the team must collect pre-pilot and post-pilot data. This data will allow the team to
acknowledge the success of the pilot project and change protocol. 32 Once the pilot stage is
complete; the EBP team will decide if the change is appropriate for practice. If the change is
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indeed appropriate, the EBP team will redesign the practice change and integrate it into routine
practice. Once the above step is accomplished, the team will engage other stakeholders to
implement the change. The final stage will be to disseminate the findings. The team will share
reports within and outside of the organization.
The rationale for the Iowa model is that the process is simple and allows the team to monitor
expected benefits before rolling the program throughout the healthcare facility. The team must
have a pilot program to determine if the change protocol will fit the facility’s goals and
mission.32,33 The model also allows only high-priority issues to run to completion. The above
ideas allow the EBP team to limit wastage of resources and ensure certainty for quality and
positive outcomes. The model also ensures patient safety, especially before the project is
mandated throughout all healthcare facilities and surgical units. Therefore, the Iowa model is a
safe design for ensuring a safe transition for the reduction of opioids and to increase
dexmedetomidine use.

Evaluation Plan
The evaluation process will be based on the Iowa model of project evaluation. The process will
include collecting and analyzing post-pilot data and comparing it with baseline data. 32,33 Also, the
evaluation plan will acknowledge verbal feedback from the project implementers. Feedback will
be evaluated to determine if dexmedetomidine was a successful adjunct, thereby meeting
objectives. Baseline and post-pilot data will include information about opioid consumption,
quality of recovery score, pain intensity, length of hospital stay, the incidence of nausea and
vomiting, time of request of the first analgesia, time to the first use of rescue analgesia, and
postoperative depression. This feedback may provide insights into necessary adjustments. Once
all the data is well-organized, the EBP team will decide whether to adapt, adopt, or reject the
proposed change.33
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Sustaining the Practice Change
Once the proposed change has been determined to reduce the consumption of opioids, the EBP
team will lobby for policy formulation. Currently, no policy mandates which analgesics to be
used in the hospital. This gap in hospital policies is a promising avenue to sustain the change. A
policy can ensure that all surgical teams adopt the change to improve patient outcomes. Ideally, a
policy is a way of integrating the change into practice.32 Once the team has analyzed and certified
the data and has made recommendations for adopting the change, they will develop a policy. To
this end, the policy would be known as "reducing opioid use with dexmedetomidine."
Formulating such a policy will guide anesthesia providers in actively taking steps to reduce
opioid dosages in the perioperative period. The next strategy would be to involve in-service
education.32 In-service education is warranted because the project implementation should include
all surgical units and will ensure that all providers understand the rationale behind the policy
change. In-service education will also improve compliance with the policy.
The final protocol would be a plan for continuous monitoring and reporting of data. Frequent
monitoring will project how the goals and outcomes of the project are being met. 32 Monitoring
will also acknowledge necessary adjustments such as dose adjustments and timing of the
dexmedetomidine administration. Frequent monitoring will be vital for procuring evidence that
the change is necessary. The EBP team will report to the organization and other organizations as
well as this will be vital for a nationwide approach to the opioid pandemic. Once the project
receives national interest, it’s implementation within the healthcare facility will be solidified.
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Appendix B: Matrix Tables
Evaluation table 1
Citation

Ren C, Xu H, Xu G, et al. Effect of intraoperative infusion of dexmedetomidine
on postoperative recovery in patients undergoing endovascular interventional
therapies: A prospective, randomized, controlled trial. Brain and behavior.
2019;9(7):e01317. doi:10.1002/brb3.1317

Design/Method

Prospective randomized controlled trial: 86 patients undergoing EITs randomized
into three groups. All groups had dexmedetomidine at an initial dose of 0.5 µg/kg
for 10 minutes. Dose adjustment varied per group throughout the EIT. RD1 dose
was adjusted to 0.2 µg/kg-1 hr-1; RD2 adjusted to 0.4 µg/kg-1 hr-1; RD3 0.6 µg/kg-1
hr-1

Sample/Setting

86 patients (ASA I or II), BMI < RD1 n=29, RD2 n=28, and RD3 n=29. Patients
adults of age 60-75 undergoing endovascular interventional therapies in PACU

Major Variables

Dependent variables: Intraoperative variables such as duration of surgery,

Studied and

duration of anesthesia, remifentanil dosage, dexmedetomidine, nimodipine

Their Definitions

dosage, propofol dosage, and cisatracurium dosage; postoperative variables such
as recovery time at PACU, duration of hospitalization, patient satisfaction score,
surgeon satisfaction score, GOS of three months, and cerebral infarction after 30
days.
Independent variable: dexmedetomidin administration.

Measurement

IntelVue monitor: Used to obtain intraoperative hemodynamic data

and Data

Glasgow coma scale: Used for neurologic examination

Analysis

Bruggrmann comfort scale obtained at 1, 4, 8, 16, and 24 hrs after surgery

Findings

Dexmedetomidine at an initial dosage of 0.5 µg/kg adjusted to 0.6 µg/kg-1 hr-1
reduced the consumption of total nimodipine and sufentanil and narcotic drugs
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during surgery. Surgeon's satisfaction was low, and the length of hospital stay was
increased at 0.5 after surgery. More patients in RD3 needed atropine than RD1
and RD2.
Results

RD2 and RD3 showed a more stable hemodynamic profile than RD1. GCS, BCS,
and FAS were not statistically significant across groups.

Conclusions

Dexmedetomidine can be used to reduce opioid consumption in the first 48 hours
of surgery with better pain scores

Appraisal:

Strength: Consistent and stepwise administration of dexmedetomidine Limitations

Worth to

include small sample size, inability to assess plasma levels of dexmedetomidine

Practice/Level

and catecholamines. Feasibility of use: Results are appropriate to inform practice

THEME

Reducing opioid consumption in surgical units.

Evaluation table 2
Citation

Shin, Hyun-Jung, et al. "Comparison of intraoperative sedation with
dexmedetomidine versus propofol on acute postoperative pain in total knee
arthroplasty under spinal anesthesia: a randomized trial." Anesthesia & Analgesia
129.6 (2019): 1512-1518. doi: 10.1213/ANE.0000000000003315.

Design/Method

Block randomized controlled trial: 48 patients randomized into dexmodetimine
(dex) group n=24 or propofol group n=24. Dexmedetomidine group received a
loading dose 1 µg/kg dexmedetmidine over 10 minutes. They received additional
dex 0.1-0.5 2 µg/kg-1 hr-1. The propofol group received a dose between 0.5-2.0
µg/mL.
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Sample/Setting

Fifty-four participants (ASA I or II) dex group, n=24, or propofol group, n=24,
scheduled for total knee arthroplasty in a hospital setting. Age range was 20-80
years

Major Variables
Studied and
Their Definitions
Measurement
and Data

Independent variable: Dexmedetomidine vs. propofol infusion
Dependent variable: postoperative cumulative fentanyl consumption via IV PCA,
NRS scores, postoperative pain burden, serial SBPs, and HRs,
Variables were analyzed using the Shapiro-Wilk test. Other statistical tests such
as the Fischer exact test, Friedman test, and Kruskal Wallis test were used.

Analysis
Findings

Administration of dexmedetomidine that propofol reduced postoperative opioids
consumption and pain scores 48 hours after surgery.

Results

Postoperative fentanyl consumption was significantly reduced in the
dexmedetomidine group. The baseline NRS scores were not significantly different
in both groups. At six hours, the postoperative NRS scores were lower in the
dexmedetomidine group compared to the propofol group. There was no
significant difference in postoperative serial systolic blood pressure (SBP) and
heart rate (HR) in both groups.

Conclusions

Intraoperative dexmedetomidine infusion causes a clinically significant reduction
in opioid consumption in patients undergoing total knee arthroplasty.

Appraisal:
Worth to
Practice/Level

Strength: Robust pain management protocol. Limitation: sedation levels were not
assessed at PACU. Risk of harm: Reduced by excluding patients with
contraindications to spinal anesthesia. Feasibility of use: Appropriate, the protocol
is easily reproducible.

THEME

Reducing opioid consumption in surgical units.

Page 55 of 74

Evaluation table 3
Citation

Sherif AA, Elsersy HE. The impact of dexmedetomidine or xylocaine continuous
infusion on opioid consumption and recovery after laparoscopic sleeve
gastrectomy. Minerva anestesiologica. 2017;83(12):1274-1282.
doi:10.23736/S0375-9393.17.11855-9

Design/Method

Prospective RCT: 150 patients randomized into the control lidocaine or dex
groups. Control group: saline bolus and continuous infusion. Lidocaine group: 2
mg/kg bolus over ten minutes followed by 1.5 mg/kg/hr continuous infusion.
Dexmedetomidine group: 1 µg/kg bolus over ten minutes, followed by 0.4 µg/kg
continuous infusion.

Sample/Setting

150 patients (ASA I to II, BMI > 40 kg/m2 or > 35 kg/m2 with comorbidities)
scheduled for laparoscopic bariatric surgery in a hospital setting.

Major Variables
Studied and
Their Definitions
Measurement

Dependent variables: Primary variable; total morphine consumption. Other
variables were pain score and quality of recovery.
Independent variable: dexmedetomidine vs. lidocaine infusion.
Wilson’s four-point sedation scale was used to examine the degree of sedation in

and Data

PACU.

Analysis

Emotional scale, physical comfort, psychological support, physical dependence,
physical support, and pain domains were used to examine the quality of recovery.

Findings

Continuous infusion of dex or lidocaine reduced total morphine require and
improve the quality of recovery.

Results

Total morphine consumption was 14 (dexmedetomidine group), 18 (lidocaine
group), and 29 (control). This means including both dexmedetomidine or
lidocaine reduces morphine consumption while dexmedetomidine provides better
results.
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Conclusions

Continuous infusion of dexmedetomidine better reduces opioid consumption than
lidocaine.

Appraisal:
Worth to
Practice/Level

Strength: All patients monitored by capnography, electrocardiography, pulse
oximetry, and noninvasive arterial blood pressure. Limitation: The medications
were not provided preoperatively. Risk of harm: Minimal through careful
monitoring. Feasibility of use: Adequate results to support applicability.

THEME

Reducing opioid consumption in surgical units.

Evaluation table 4
Citation

Bielka K, Kuchyn I, Babych V, et al. Dexmedetomidine infusion as an analgesic
adjuvant during laparoscopic сholecystectomy: a randomized controlled study.
BMC Anesthesiology. 2018;18(44):1-6. doi:10.1186/s12871-018-0508-6

Design/Method

Single-centered, parallel-group placebo-controlled RCT: 60 patients n=30 group
C and n=30 group D. Group D patients received dexmedetomidine 0.5 µg/kg.
Patients in group C received normal saline.

Sample/Setting

60 patients (ASA I-II) elected to laparoscopic cholecystectomy. Patients were
aged 18-79. Patients were in a hospital setting.

Major Variables

Dependent variable: postoperative morphine consumption in the first 24 hours.

Studied and

Cumulative hospital stay. Other variables include the incidence of post-surgical

Their Definitions

pain, length of intensive care unit stay, intraoperative fentanyl consumption, time
of use of first rescue analgesia, and the number of patients with severe pain.
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Measurement
and Data

Richmond's agitation sedation scale and the verbal rating scale were used for
sedation and pain, respectively.

Analysis
Findings

Dexmedetomidine 0.5 µg/kg reduces postoperative requirements for opioid
analgesics and increase the sedation level.

Results

There was no significant difference in postoperative pain levels in both groups.
Dexmedetomidine infusion reduced the incidence of severe pain and increased the
time to use of first rescue analgesia. Dex infusion also reduced postoperative
morphine consumption (at mean 5 mg/ 24 h vs. 15 mg/24 h in group D). length of
ICU stay was not statistically different that is 14 h group D and 13 h group C.

Conclusions

Dex infusion is an effective modality for better analgesic outcomes during
elective laparoscopic cholecystectomy.

Appraisal:
Worth to
Practice/Level

Strength: Proper monitoring through Philips vital signs monitor, BIS, and ANIimproved outcomes. Limitation: small sample size. Risk of harm: minimal,
patients ASA I and II selected. Feasibility of use: Applicable in practice, as shown
by data and results.

THEME

Reducing opioid consumption in surgical units.

Evaluation table 5
Citation

Kang RA, Jeong JS, Yoo JC, et al. Improvement in postoperative pain control by
combined use of intravenous dexamethasone with intravenous dexmedetomidine
after interscalene brachial plexus block for arthroscopic shoulder surgery: A
randomized controlled trial. European Journal of Anaesthesiology (EJA).
2019;36(5):360-368. doi:10.1097/EJA.0000000000000977
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Design/Method

RCT: 66 patients randomly assign to control group (IV 0.9% saline), D1 group
(0.11 mg/kg IV dexamethasone), and D2 group (IV dexmedetomidine 1 µg/kg +
IV dexamethasone 0.11 mg/kg).

Sample/Setting

66 patients (ASA I-III) scheduled for elective unilateral arthroscopic shoulder
surgery. The setting was a single tertiary care center.

Major Variables
Studied and
Their Definitions

Independent variables IV saline, dexamethasone, and dexmedetomidine infusion.
Dependent variables: Time to first rescue analgesic request. Other independent
variables include the duration of motor blockade, pain severity, and total
postoperative opioid consumption.

Measurement
and Data

Visual analogue scale (VAS) was used for pain.
Richmond agitation-sedation scale was used to assess sedation.

Analysis
Findings

Combining dexamethasone 0.11 mg/kg with dexmedetomidine 1 µg/kg increases
the time to the first rescue analgesia by 3.8 fold.

Results

The D2 group had a significantly longer to first rescue analgesic request. This was
about 66.3 h compared to 17.4 h in D1. D1 and D2 had lower pain scores and
postoperative opioid consumption.

Conclusions

Coadministering dexamethasone 0.11 mg/kg with dexmedetomidine 1 µg/kg
improves analgesia.

Appraisal:
Worth to
Practice/Level

Strength: Having a dexamethasone only group which eases comparison with the
dexamethasone and dexmedetomidine group. Limitation: There was no
dexmedetomidine-only group. Risk of harm: Minimal, included ASA I-III.
Feasibility of use: Applicable to practice since the protocol is replicable.

THEME

Reducing opioid consumption in surgical units.
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Evaluation table 6
Citation

Uusalo P, Jätinvuori H, Löyttyniemi E, Kosola J, Saari TI. Intranasal Low-Dose
Dexmedetomidine Reduces Postoperative Opioid Requirement in Patients
Undergoing Hip Arthroplasty Under General Anesthesia. Journal of Arthroplasty.
2019;34(4):686-692.e2. doi:10.1016/j.arth.2018.12.036

Design/Method

Retrospective study. 120 patients divided into two groups, group 1 50 µg/kg
dexmedetomidine and group 2 conventional therapy.

Sample/Setting

120 patients (ASA I-II) enrolled for unilateral primary hip arthroplasty with total
IV anesthesia. The study was conducted in a hospital setting.

Major Variables
Studied and
Their Definitions

Independent variable: Intranasal dexmedetomidine. LIA- block with 145 mL of
0.125% levobupivacaine and 5 mL of epinephrine 0.01%
Dependent variable: the amount of opioid administered. Other variables include
MAP, HR values.

Measurement

VAS was used to rate pain

and Data

Shapiro-Wilks test was used to assess normality assumptions.

Analysis

Wilcoxon's rank sum test was used for normality distributed data.

Findings

Intranasal administration of 50 µg/kg dex reduces opioid consumption in patients
undergoing unilateral primary hip arthroplasty

Results

Postoperative opioid requirement was low in the dex group. This included the
mean requirement of 152 mg and 178 mg in dex group and control, respectively.
More NSAIDs were used in the control group than the dex group.

Conclusions

Dexmedetomidine 50 µg/kg given intranasal offers comparatively better analgesic
effects.
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Appraisal:
Worth to
Practice/Level
THEME

Strength: No adverse events were reported. Limitation: The study lacked
randomization. Risk of harm: Minimal, the study includes ASA I-II patients.
Feasibility for use: Applicable to practice since the protocol is not complicated.
Reducing opioid consumption in surgical units.

Evaluation table 7
Citation

Li J, Yang JS, Dong BH, Ye JM. The Effect of Dexmedetomidine Added to
Preemptive Ropivacaine Infiltration on Postoperative Pain After Lumbar Fusion
Surgery: A Randomized Controlled Trial. Spine (Phila Pa 1976).
2019;44(19):1333-1338. doi:10.1097/BRS.0000000000003096

Design/Method

RCT: 57 patients randomized into group R, 20 mL 0.5% ropivacaine and group
RD 20 mL 0.5% ropivacaine coadministered with dexmedetomidine 1µg/kg. all
patients received postoperative morphine.

Sample/Setting

57 patients (aged between 18 to 75 years, ASA I-II, BMI≥30) scheduled for
elective posterior lumbar interbody fusion surgery. R n=28, and R n=29

Major Variables
Studied and
Their Definitions
Measurement

Independent variable: Dexmedotimidine vs. ropivacaine infusion.
Dependent variable: Total consumption of IV morphine in the first 24 hours after
surgery. Time of first analgesic demand.
VAS was used to rate pain.

and Data
Analysis
Findings

Adding dexmedetomidine to preemptive ropivacaine lowers postoperative
morphine consumption and prolongs time to the first rescue analgesia.
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Results

The mean PCA morphine consumption in the RD group was 16.5, while the R
group was 7.6. more morphine was consumed in the RD group. The RD group
had a prolonged time for the request of the first analgesic, which is 10.5 hours. R
group had a short time to the request of the first analgesic, which is 5.3 hours.
There was a marked reduction in the VAS score in RD than the R group.

Conclusions

Dexmedetomidine/ropivacaine combination improves analgesia and reduces
opioid consumption.

Appraisal:

Strength: Ability to demonstrate clinical benefits of combination therapy.

Worth to

Limitation: Only a single dose of both medicines were used. Risk of harm:

Practice/Level

Minimal, ASA I-II patients included. Feasibility of use: Adequate conclusion
supported by sufficient data.

THEME
Evaluation table 8
Citation

Reducing opioid consumption in surgical units.

Chan, I. A., Maslany, J. G., Gorman, K. J., O’Brien, J. M., & McKay, W. P.
(2016). Dexmedetomidine during total knee arthroplasty performed under
spinal anesthesia decreases opioid use: a randomized-controlled
trial. Canadian Journal of Anesthesia/Journal canadien d'anesthésie, 63(5),
569-576.

Design/Method

Double-blind randomized-controlled test involving 40 patients.
First group received a 0.5 lgkg-1 dose of dexmedetomidine within 10 minutes,
then an additional 0.5 lgkg-1 infused throughout the entire surgery. The second
group received normal saline

Sample/Setting

40 patients (ASA I-III) aged between 18-15 years expecting a knee arthroplasty.
The study was carried out in a hospital setting.
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Major Variables
Studied and

Height, weight, age ASA physical status, BMI, duration of surgery and
gestational age

Their Definitions
Measurement

visual analogue scale (VAS) was used to measure pain levels.

and Data
Analysis
Findings

Dexmedetomidine is an effective anesthesia for patients undergoing caesarian
section.

Results
Conclusions
Appraisal:
Worth to

Intravenous DEX led to reduced requirement for postoperative opioid in patients.
Dex infusion is an effective anesthesia and sedative.
Strength: adequate sample size. Limitation: Level of patient sedation not
measured. Risk of harm: low. Feasibility of use: can be applied in clinical setup.

Practice/Level
THEME
Evaluation table 9
Citation

Safety and efficacy of Dexmedetomidine in Caesarian section patients.

Lee, C., Lee, C., So, C., Lee, J., Choi, I., Ma, X., & Hwang, J. (2020). Impact
of Dexmedetomidine on Tourniquet-Induced Systemic Effects in Total Knee
Arthroplasty under Spinal Anesthesia: a Prospective Randomized, DoubleBlinded Study. BioMed Research International, 2020.

Design/Method

Randomized test involving total knee arthroplasty (TKA) patients categorized into
2 groups: Control and dexmedetomidine.

Sample/Setting
Major Variables

80 pediatric patients (ages 20-80) going through going through TKA
Age, sex, height, weight, ASA classification, surgery duration

Studied and
Their Definitions
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Measurement

PASS 2008 was utilized in calculating the sample size.

and Data
Analysis
Findings

There was a considerable difference in the amount of fentanyl needed after
surgery between the two groups

Results
Conclusions

DEX reduced the need of fentanyl post operation in TKA patients
DEX prolongs analgesic period hence reduces the requirement for fentanyl use
after surgery

Appraisal:
Worth to
Practice/Level
THEME

Strength: Adequate sample to provide bias-free results. Limitation: taking two
sequential blood samples from one patient. Risk of harm: low. Feasibility of use:
can be applied in clinical practice.
Effect of DEX on administration of fentanyl post-surgery

Evaluation table 10
Citation
Li, X. X., Li, Y. M., Lv, X. L., Wang, X. H., & Liu, S. (2020). The efficacy
and safety of intrathecal dexmedetomidine for parturients undergoing
cesarean section: a double-blind randomized controlled trial. BMC
anesthesiology, 20(1), 1-9.
Design/Method

300 parturients due for caesarian section being treated to spinal anaesthesia were
grouped into 3 categories:
Group B: 9.0 mg of bupivacaine (0.75%) together with 1 ml saline
Group FB: 9.0 mg of bupivacaine (0.75%) together with 1 ml fentanyl (20 μg)
Group DB: 9.0 mg of bupivacaine (0.75%) together with 5 μg of DEX (1 ml).

Sample/Setting

300 patients under spinal anesthesia.

Page 64 of 74

Major Variables
Studied and

Height, weight, age ASA physical status, BMI, duration of surgery and
gestational age

Their Definitions
Measurement

PASS 15.0 software was used in the analysis of data.

and Data
Analysis
Findings

Dexmedetomidine 0.5 µg/kg has a block effect on which reduces the need for
analgesics after surgery.

Results

There was no major difference in postoperative levels of pain across the three
groups, including period of surgery, peak sensory level, and blood loss.
Groups FB and DB demonstrated prolonged periods of sensory block compared to
Group B; Group B (108.4 min), Group FB (122.0 min), and Group DB (148.2
min).

Conclusions

Dex has the potential to improve the quality of parturients’ recovery by causing a
block effect particularly in a 5 μg DEX combination.

Appraisal:
Worth to
Practice/Level

Strength: use of ANOVA software left limited room for error.
Limitation: the sample was too small.
Risk of harm: low. Feasibility of use: results from study can be applied in clinical
settings.

THEME

Efficacy and safety of Dex for patients experiencing caesarian section.

Evaluation table 11
Citation
Chan, I. A., Maslany, J. G., Gorman, K. J., O’Brien, J. M., & McKay, W. P.
(2016). Dexmedetomidine during total knee arthroplasty performed under
spinal anesthesia decreases opioid use: a randomized-controlled
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trial. Canadian Journal of Anesthesia/Journal canadien d'anesthésie, 63(5),
569-576.
Design/Method

Randomized test involving ASA I or II patients categorized into two groups: D
(bupivacaine plus 5mg Dex) and C (bupivacaine plus equal amount of saline)
Subsequent dose of bupivacaine depended upon the enhanced up-down allocation
process. The starting bupivacaine dose for both groups was 4 mg and was
increased subsequently based on the probability of the present dose.

Sample/Setting

90 patients (ASA I or II) going through caesarean section in spinal anesthesia.

Major Variables

Height, weight, age ASA physical status, BMI, duration of surgery;( that is, the

Studied and
Their Definitions
Measurement
and Data

period from the onset of the surgery until its completion), and period until
recovery.
Logistic regression model was used to calculate ED95. Normal distribution was
estimated using the Kolmogorov-Sminorv test.

Analysis
Findings

Group C recorded higher ED95 and 95% CI (confidence interval) than Group D

Results

Intrathecal 5mg DEX increases the efficacy of spinal bupivacaine by at least 24%.

Conclusions

DEX prolongs analgesic period in and enhances efficacy of spinal bupivacaine in
patients undergoing caesarian section.

Appraisal:
Worth to
Practice/Level
THEME

Strength: Adequate sample to provide bias-free results. Limitation: small sample
size, and absence of measurements to determine neurological deficit. Risk of
harm: minimal. Feasibility of use: can be applied in clinical practice.
Effect of DEX on spinal bupivacaine.

Evaluation table 12
Citation
Fares, K. M., Mohamed, S. A. B., Abd El-Rahman, A. M., AbdeLemam, R.
M., & Osman, A. M. M. (2020). Analgesic Effect of Intrathecal Fentanyl vs
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Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal
Surgery for Cancer in Children, a Randomized Trial. Pain Medicine, 21(11),
2634-2641.
Design/Method

Randomized double-blind test involving ASA I or II malignancy patients
categorized into 3 groups: C (2ml bupivacaine); F (2mg bupivacaine plus fentanyl
0.2 mg/kg); and D (2 ml bupivacaine + dexmedetomidine 0.2 lg/kg)

Sample/Setting

60 pediatric patients (ages 3-13) going through going through malignancy
treatment

Major Variables
Studied and
Their Definitions

Systolic blood pressure (SBP),
Diastolic blood pressure,
heart rate,
sedation score

Measurement
and Data

Pain score was measured using the Face, Legs, Activity, Crying, and
Consolability (FLACC).

Analysis
Findings
Results
Conclusions

Intrathecal narcotics can be effective anesthesia during surgery
Systolic blood pressure (SBP) was lower in group D than in C and F
DEX prolongs analgesic period in and enhances efficacy of spinal bupivacaine in
patients undergoing surgery

Appraisal:
Worth to
Practice/Level
THEME

Strength: Adequate sample to provide bias-free results. Limitation: small sample
size, and absence of measurements to determine neurological deficit. Risk of
harm: minimal. Feasibility of use: can be applied in clinical practice.
Effect of DEX on spinal bupivacaine.
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Appendix C:
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Appendix D:

Pretest and Posttest Questionnaire:
The Utilization of Dexmedetomidine as an Anesthetic Adjunct in Spinal Anesthesia to
Reduce Perioperative Consumption of Opioids
INTRODUCTION
The primary aim of this QI project is to improve the knowledge of CRNAs pertaining to the
utilization of dexmedetomidine as an anesthetic adjunct in spinal anesthesia in order to reduce
perioperative consumption of opioids.
Please answer the question below to the best of your ability. The questions are either in
multiple choice or true/false format and are meant to measure knowledge and perceptions on the
utilization of dexmedetomidine as an anesthetic adjunct in spinal anesthesia to reduce
perioperative consumption of opioids.
PERSONAL INFORMATION
1. Gender: Male

Female

Other________

Caucasian

African American

2. Age: ______
3. Ethnicity:
Hispanic

Asian

Other_______________
4. Position/Title: _________________________________
5. Level of Education: Associates

Bachelors

Masters

___________
6. How many years have you been an anesthesia provider?
Over 10

5-10 years

2-5 years
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1-2 year

Other

QUESTIONNAIRE
1. 6% of previously opioid naïve surgical patients continued taking opioids _____ post-surgery:
a. 2-4 weeks
b. 1-2 months
c. 3-6 months
d. 1-2 years
2. Adverse effects of chronic opioid consumption include:
a. Urinary retention
b. hyperalgesia
c. respiratory depression
d. bradycardia
e. somnolence
f.

all of the above

3. In 2018, it was reported that _____ Americans 12 years and older partook in the misuse of
opioids:
a. 5.2 million
b. 10.3 million
c. 15 million
d. 18.4 million

4. Since 1999, more than _________ Americans have died from an opioid overdose:
a. 120,000
b. 250,000
c. 500,000
d. 760,000
5. Dexmedetomidine is a:
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a. α2-adrenergic receptor agonist
b. α2-adrenergic receptor antagonist
c. β1-adrenergic receptor agonist
d. β2-adrenergic receptor antagonist
6. The benefits of Dexmedetomidine include:
a. Causes minimal respiratory depression
b. Has analgesic properties
c. Prevents postoperative delirium
d. All of the above
7. Select the true statement:
a. Dexmedetomidine increases the need of opioid administration
b. Dexmedetomidine increases MAC and response to intubation
c. Dexmedetomidine can cause hypotension, hypertension, nausea, bradycardia, anemia, and
hypothermia
d. Coadministration of dexmedetomidine with anesthetics, sedatives, hypnotics, and opioids is
likely to lead to a decrease of their effects
8. Dexmedetomidine given at 1 µg/kg IV loading dose over 10 minutes, followed by 0.4 µg/kg/h
reduces total morphine consumption by at least ______.
a. 15%
b. 20%
c. 35%
d. 50%
9. How likely are you to use dexmedetomidine as an anesthetic adjunct in patients receiving spinal
anesthesia?
a. Most likely
b. Somewhat likely
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c. Somewhat unlikely
d. Most unlikely
10. How likely are you to recommend utilizing dexmedetomidine as an anesthetic adjunct in
patients receiving spinal anesthesia?
a. Most likely
b. Somewhat likely
c. Somewhat unlikely
d. Most unlikely
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Appendix E: Educational PowerPoint
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Appendix F: Poster
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